Imidapril (imidapril) nephropathy is a long action, non-sulfhydryl converting enzyme (ACE) inhibitor used in the treatment of hypertension, chronic heart failure (CHF), acute myocardial infarction (AMI) has been used clinically, and diabetic. It caused the unique advantage over other ACE inhibitors in a lower incidence of dry cough. After oral administration, the administration imidapril is rapidly converted in the liver to its active metabolite imidapril. Plasma levels of imidapril gradual increase in proportion to the dose and slowly decrease. Time to maximum plasma concentration (T (max)) is 2.0 hours to 9.3 hours and imidapril to reach for imidaprilat. The half-life of elimination (t (1/2)) of imidapril and imidaprilat is 1.7 and 14.8 h, respectively. Imidapril and its metabolites are excreted primarily in the urine. When ACE inhibitors, imidaprilat is as effective as enalapril, an active metabolite of enalapril, and about twice as high as captopril. In hypertensive patients, blood pressure was reduced to 24 hours after administration of imidapril. The antihypertensive effect of imidapril was dose-dependent. The maximum decrease in blood pressure and plasma ACE has been performed with imidapril, 10 mg once daily, and the additive effect was not evident with the higher doses. In patients with an acute myocardial infarction, imidapril improved ventricular ejection fraction and reduces brain natriuretic peptide plasma (BNP). In patients with mild to moderate CHF [New York Heart Association (NYHA) II-III], imidapril increased exercise time and physical work capacity and a decrease in plasma ANP (ANP) and the rate of BNP in a dose-dependent manner. In patients with diabetic nephropathy, imidapril reduces urinary albumin excretion. Interestingly, improving imidapril dysphagia asymptomatic patients with a history of stroke. In the same patient, it increases the serum levels of substance P while the Angiotensin II receptor antagonist, losartan was ineffective. These studies show that imidapril is an inhibitor of ACE versatile. In addition to its effectiveness in the treatment of hypertension, CHF, and AMI imidapril has beneficial effects in the treatment of diabetic nephropathy and asymptomatic dysphagia. Good penetration in tissues and inhibition of tissue ACE by imidapril contribute to its effectiveness in cardiovascular complications of hypertension to prevent. The main advantages of imidapril are its activity in the treatment of various cardiovascular diseases and a lower incidence of cough in comparison with some of the older ACE inhibitors.
